WALNUT CREEK, Calif. (PRWEB)
July 01, 2020

Conductiv™, formerly Medpricer, unveiled its new brand and integrated suite for purchased services cost optimization today with the launch of Conductiv Platform™, Conductiv Services™ and Conductiv Contracts™. The rebrand positions Conductiv, the leading end-to-end third-party services optimization company, to broaden its offerings and expand into new markets.

“Third-party services optimization has emerged as a top target for supply chain and finance executives looking to implement cost-saving initiatives,” said Chris Gormley, CEO of Conductiv. “Third-party services include purchased services as well as IT, construction, clinical, HR, marketing and administrative categories. Conductiv’s proprietary spend database shows that organizations spend 22 to 54 percent of their non-labor expenses on third-party services, representing a crucial, untapped source of margin improvement – especially with Conductiv’s ability to drive savings of 24 percent, on average.”

Conductiv empowers supply chains by integrating its technology and proven category expertise – including analytics driven by artificial intelligence, marketplace insights and express contracting negotiation capabilities – onto one integrated cloud-based platform. Its sourcing automation technologies enable members to engage with their own spend data, determine the competitiveness of their contracts, optimize group purchasing organization (GPO) contracts, unite business stakeholders, create transparency on services spend, and accelerate the speed of identifying and implementing cost savings.

Conductiv’s integrated third-party services optimization suite consists of:

• Conductiv Platform™, a sophisticated, purpose-built procurement automation platform powered by artificial intelligence and machine learning. Drawing insights from large and comprehensive data sets on supplier quality, pricing and service regions, this predictive analytics engine works to maximize savings and gain end-user engagement while minimizing operational risks.
• Conductiv Services™, a sourcing service that brings in more than 15 years of proven strategic sourcing results. Conductiv Services offers deep category insight, proven sourcing processes, program development and stakeholder governance delivered to meet an organization’s bespoke needs. Unlike traditional consultants, Conductiv Services are boosted by Conductiv Platform to provide specialized, data-driven insights that enhance savings based on the organization’s opportunity areas.
• Conductiv Contracts™, a first-of-its-kind GPO that works alongside any primary GPO and accelerates the time for organizations to source, negotiate and implement contracts with third-party service providers. Membership is free and open to all organizations regardless of primary GPO affiliation. Conductiv soft-launched its GPO to its customers in April and launches publicly today with inaugural members that include Hennepin Healthcare, McLaren Health Care and Pandion Optimization Alliance.

“We see Conductiv’s rebrand and new positioning as a gamechanger for Pandion,” said Jeanie Smith, Chief Operating Officer of Pandion Optimization Alliance, which serves 17 hospitals and their related health systems in New York state. “Conductiv’s technology alone will allow our members to have greater visibility and control of a significant spend area of spend. In addition, Conductiv Contracts will enable our healthcare systems to partner with our local purchased service providers to not only improve quality and cost, but also increase jobs, within their communities. We are thrilled to be an inaugural member.”

The capability to source contracts from domestic and diversity businesses has emerged as a driving force post-pandemic, as more organizations seek ways to support local communities and improve regional economies. Conductiv Contracts’ technology-enabled sourcing process ensures that suppliers of local, regional and national presence can now compete equally for business within their respective markets.

“With access to a portfolio of local and regional suppliers, Conductiv Contracts gives us the opportunity to better support our local community and unite stakeholders across our organization in our choice of outsourced services,” said David Bueby, Corporate Vice President of Supply Chain Management of Michigan-based McLaren Health Care. “In addition, with greater transparency on our third-party services spend, we’re able to accelerate the speed of our RFPs and negotiations. We’re excited to be an inaugural member of Conductiv Contracts as we aim to increase transparency into spend data and better assess the competitiveness of our own third-party contracts.”

“Hennepin Healthcare has had a very successful relationship with Medpricer and we are looking forward to continuing and expanding our best practice journey with Conductiv,” explained Luis Valadez, Sr. Director of Supply Chain, of Minneapolis-based Hennepin Healthcare. “As healthcare changes, supply chain is looked at to ensure value and to be at the forefront of driving results. Our continued relationship with Conductiv will ensure we meet these goals. We are excited to be a part of this new offering.”

More than ever, organizations must urgently solve financial gaps with minimal impact to their future operations and local communities. Conductiv’s solutions optimize 22-54% of non-labor operating costs, helping executives solve those financial challenges with immediate impact.

For more information, please visit https://conductiv.com.

About Conductiv

Conductiv™, formerly Medpricer, empowers supply chains to optimize their third-party services. As the only end-to-end third-party lifecycle improvement company, Conductiv™ shares its strategic sourcing expertise and category best practices with multiple industries including healthcare, hospitality, government, real estate, transportation and education. The company has led more than 700 bids for more than 120 organizations, exceeding $4 billion in contracted value. Member projects have generated $800 million of documented savings or an average savings value of 24% to date. To learn how supply chains are transforming their savings strategy, visit https://conductiv.com.

Share article on social media or email:

“Non-Hodgkin’s Lymphoma is a devastating disease, and many of our clients continue to suffer the effects of this cancer,” said Andrew Jones, attorney at Cory Watson. “This settlement should help our clients rebuild and move forward in a meaningful way.”

BIRMINGHAM, Ala. (PRWEB)
July 01, 2020

Cory Watson Attorneys, alongside many other plaintiff’s firms, have reached a $10.95 billion settlement with Monsanto on behalf of thousands of plaintiffs who claim that exposure to Roundup, the world’s most popular weed killer, caused their cancer.

Cory Watson has filed multiple lawsuits on behalf of plaintiffs against Monsanto, alleging that exposure to their widely used herbicide Roundup was causing Non-Hodgkin’s Lymphoma in farmers, landscapers, maintenance workers, and homeowners.

“It has been a long journey, but we are pleased to find closure for our clients through this settlement,” said Douglas A. Dellaccio Jr., principal attorney and Complex Litigation Practice Co-Chair at Cory Watson.

For nearly 40 years, farmers around the world used Roundup without knowledge of the dangers posed by its use. Monsanto, the maker of Roundup, has failed to place a warning label on its product informing the consumer that the product contains dangerous agricultural chemicals.

In 2015, the World Health Organization found that glyphosate, the principal “weed killer” component of Roundup, is carcinogenic to humans. Monsanto continues to insist that Roundup is harmless and poses no danger to its users, saying it has no plans to pull the product from the market.

“This $10 billion settlement is big news for anyone who may have been exposed to glysophate’s carcinogenic effects,” said J. Curt Tanner, principal attorney at Cory Watson.

The settlement between Monsanto and plaintiffs is being overseen by court-appointed mediator Kenneth Feinberg, who previously managed compensation funds after September 11 and the explosion of the BP Deepwater Horizon oil rig in the Gulf of Mexico.

“Non-Hodgkin’s Lymphoma is a devastating disease, and many of our clients continue to suffer the effects of this cancer,” said R. Andrew Jones, attorney at Cory Watson. “This settlement should help our clients rebuild and move forward in a meaningful way.”

Monsanto faces thousands of lawsuits in federal and state courts over the herbicide. Three cases have gone to trial, with juries returning verdicts of $289 million, $80 million, and $2 billion against Monsanto.

About Cory Watson Attorneys

Cory Watson Attorneys is a nationally recognized personal injury and environmental tort law firm with offices in Birmingham, Alabama; Memphis, and Nashville, Tennessee. The firm has recovered more than $2.7 billion for clients across the country. Cory Watson attorneys are frequently at the forefront of major class actions and multidistrict litigations involving dangerous pharmaceuticals and product liability, and are often appointed to leadership positions in national cases. Firm practice areas include Personal Injury, Product Liability, Class Action, Asbestos, Business & Commercial Litigation, Dangerous Pharmaceuticals, Defective Medical Devices, and Environmental/Toxic Torts.

Share article on social media or email:

SCoV-2 Detect IgM ELISA

SEATTLE (PRWEB)
July 01, 2020

InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its SCoV-2 Detect IgM ELISA kit, an in vitro diagnostic test for the qualitative detection of IgM antibodies to SARS-CoV-2, the virus that causes COVID-19, in human serum. This marks the first EUA granted for an ELISA that specifically detects IgM antibodies to SARS-CoV-2 and underscores InBios’ success in developing and bringing to market high-quality ELISA kits for emerging infectious diseases.

Earlier this month, InBios received an FDA EUA for its SCoV-2 Detect IgG ELISA kit. In 2011, InBios was the first to be granted a 510(k) clearance from the FDA for its Dengue IgM ELISA kit and offered the first commercial Zika IgM ELISA under FDA’s EUA in 2016.

“We know there is still much to learn about the virus that causes COVID-19 and the disease itself, and that’s why accurate, high-quality antibody tests are so important,” said Dr. Syamal Raychaudhuri, InBios’ chief scientific officer. “InBios’ expertise in emerging infectious diseases, as well as our prior success in developing and receiving authorization for ELISA tests, has enabled us to move quickly into development of much-needed products for COVID-19. Additionally, we’ve increased production capacity and automated some manufacturing capabilities to meet worldwide demand for COVID-19 diagnostics during this pandemic.”

The specific and reliable detection of human IgM antibodies to SARS-CoV-2 may provide indication of recent infection, offering insight into the spread within communities. In performance studies, InBios’ SCoV-2 Detect IgM ELISA kit demonstrated 92.50% sensitivity and 98.95% specificity. The SCoV-2 Detect IgM ELISA kit, which is available to order immediately, includes all reagents and controls required to run 90 test specimens with results in approximately 2 hours.

InBios’s SCoV-2 Detect IgM ELISA kit is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, the virus that causes COVID-19, which may indicate recent or prior infection. At this time, it is unknown how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Samples should be tested with this kit from individuals within 7-64 days post symptom onset to avoid false negative results. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

InBios offers other products for COVID-19, including the Smart Detect SARS-CoV-2 rRT-PCR Kit and the SCoV-2 Detect IgG ELISA kit, both of which received FDA EUAs this year. InBios is also developing the SCoV-2 Detect IgM/IgG Rapid Test.

While the SCoV-2 Detect IgM ELISA kit has not been FDA cleared or approved, it has been authorized for use by the FDA under an EUA, which permits use of certain medical products that may be effective during a public health emergency, which was declared for COVID-19 on Jan. 31, 2020. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

For more information about InBios COVID-19 tests, visit: http://www.inbios.com/covid-19/.

For more information on COVID-19, please visit http://www.cdc.gov or http://www.who.int.

About InBios: InBios International Inc. specializes in the design, development and manufacture of diagnostic assays for emerging infectious diseases and biothreats. Founded in 1996 in Seattle, WA, InBios offers superior quality products which are accurate, easy to use and cost effective. InBios offers an extensive catalog of life science reagents, along with a portfolio of more than 25 diagnostic products, including FDA Emergency Use Authorized COVID-19 tests and FDA-cleared ELISA kits for Zika, dengue, and West Nile and rapid test kits for Chagas and leishmaniasis. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. For more information, visit http://www.inbios.com.

Share article on social media or email:

Sharon Kleyne, Bio Logic Aqua® Research Founder

GRANTS PASS, Ore. (PRWEB)
July 01, 2020

Sharon Kleyne on her weekly talk radio program teaches that the surface of the eye is 99 percent water. Kleyne instructs that the eyes are constantly evaporating and require a nature’s mist technology for constant supplementation and immunity protection. “Dry eye,” says Kleyne, “is over-evaporation of the eye’s tear film. There are no two eyes alike, no two fingerprints alike and no two skins alike.”

“The surface of the eye,” says ophthalmologist and chemist Dr. Philip Paden, M.D., “is the tear film. The number one role of the tear film is to fill the microscopic bumps in the cornea to give you an optical surface that allows very precise vision. The tear film,” Paden continues, “requires three layers in order to stay on the cornea and not run down and off the eye. There’s a mucous layer on top of that,” Paden continues, “and an aqueous layer that is almost 100 percent water.”

Paden also teaches that “there is an extremely thin surface on the tear film which consists of a single layer of lipids or fats. It is there to slow down evaporation. This area,” adds Paden, “is full of microorganisms. The tear film is actually an army of antibody molecules. If the eye dehydrates, the antibody molecules don’t work as well. Nature’s Tears® EyeMist® is the only tear supplement that is pure water delivered to the eye as a micron-size mist.” Paden teaches that other dry eye products flood the eye, washing away the molecular antibodies needed for immunity strengthening protection. Paden explains that a micron is a millionth of a meter, much less than a millimeter.

Kleyne’s research has learned technology immunity strengthening and protection education, pointing out that the dry eye technology of nature’s tears is an eye mist, just as the technology of Nature’s Tears® EyeMist® is 100 percent Trade Secret water and naturally pH balanced. “The technology of the pH balance is what gives the immunity strengthening protection to the eye,” says Kleyne.

“Eyes are our number one sensory input,” says Paden. “Being able to see clearly is being able to receive information you need to proceed with life.”

Paden began his professional life teaching chemistry for ten years at Cornell University. After graduating from the Albert Einstein College of Medicine if Yeshiva University in 1982 and serving his internship in Portland, Oregon, Paden has practiced ophthalmology in Medford, Oregon where he says the number one complaint he hears from patients is “uncomfortable eyes. If your eyes are uncomfortable,” says Paden, “you are unhappy and not performing at your best,” says Paden, “returns the tear film to its normal osmolarity and thickness.”

LISTEN to the internationally syndicated The Power of Water® & Your Health sponsored by Nature’s Tears® EyeMist®, naturally pH balanced water technology for acid mantel protection, on VoiceAmerica World Talk Radio & Apple iTunes with producer and host Sharon Kleyne and program director Rose Hong of Global Dragon TV. This program features ophthalmologist Philip Paden, M.D.

Follow this link: https://www.voiceamerica.com/episode/124183/immunity-protector-with-natures-tears-eyemist

Some recent programs feature:

Kevin Kearns & Steven Aithwaite

https://www.voiceamerica.com/episode/124035/earths-human-mission-a-healthier-planet

Mary Carolyn, Nutritionist https://www.voiceamerica.com/episode/123934/natural-immune-boosters

Kevin Kearns & Brandon Foster https://www.voiceamerica.com/episode/123823/strengthening-childrens-immune-system-through-fitness

Dr. Gerald Pollack, Ph.D. https://www.voiceamerica.com/episode/123059/the-fourth-phase-of-water

Kevin Kearns & Diana Healy https://www.voiceamerica.com/episode/123560/how-to-stay-active-during-the-pandemiclockdown

Dr. Gerald Pollack, Ph.D. https://www.voiceamerica.com/episode/123059/the-fourth-phase-of-water

If you would like to watch a brief, entertaining educational film that demonstrates the application of the new Dry Eye Solution® technology Nature’s Tears® EyeMist®, sponsor of Sharon Kleyne’s talk radio program, go here: https://www.youtube.com/watch?v=l0gOr8TB45U

Share article on social media or email:

“Dr. Roscoe Nelson has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
July 01, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Roscoe Nelson, M.D., Arizona Urology Specialists in Glendale, AZ, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Nelson has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“Dr. Roscoe Nelson has earned the UroLift Center of Excellence designation for his dedication to improving the lives of men who previously suffered from BPH symptoms and delivering superior patient outcomes with the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2. McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email: